Home ›
Diffuse Large B-Cell (DLBCL) Lymphoma Trials ›
NCT05940272
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Trial Details
NCT ID NCT05940272
Phase NA
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions Hematolo-GIST Training Participants Appointment
Locations (sample) New York, New York, United States|40.71427,-74.00597 New York, New York, United States|40.71427,-74.00597
Key Eligibility Criteria
Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell ly… Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider… Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) … Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy …
For full eligibility, visit ClinicalTrials.gov .